March 17, 2020 / 8:57 AM / 19 days ago

BRIEF-Astrazeneca Says Imfinzi Confirmed Overall Survival In Caspian

March 17 (Reuters) - AstraZeneca PLC:

* IMFINZI CONFIRMED OVERALL SURVIVAL IN CASPIAN

* IMFINZI CONFIRM SUSTAINED SURVIVAL BENEFIT IN FINAL ANALYSIS OF PHASE III CASPIAN TRIAL IN 1-LINE EXTENSIVE-STAGE SMALL CELL LUNG CANCER

* A SECOND IMMUNOTHERAPY, TREMELIMUMAB, ADDED TO IMFINZI, DID NOT MEET ITS PRIMARY ENDPOINT OF OVERALL SURVIVAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below